Brief: Cantargia Reports Advantages Of Nadunolimab Mechanism Of Action
Aug 30 (Reuters) - Cantargia AB CANTA.ST :
* CANTARGIA REPORTS PRECLINICAL DATA HIGHLIGHTING ADVANTAGES
OF
NADUNOLIMAB MECHANISM OF ACTION
* CAN04 INCREASED ANTI-TUMOR EFFECT OF DOCETAXEL
Source text for Eikon: ID:nNDL2dfvK3
Further company coverage: CANTA.ST
(Gdansk Newsroom)
((Gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))
Recent news on Cantargia AB
See all newsBrief: Cantargia Publishes Nadunolimab CANFOUR Study Data
Brief: Cantargia Announces Outcome Of Rights Issue, Raising About SEK 75 Mln
Brief: Cantargia Carries Out Rights Issue, Enters Loan Agreement
Brief: Cantargia Q1 Operating Loss Narrows To SEK 36.9 Mln
Brief: Cantargia: Early Results From Phase 1B/2A Nadunolimab Trial In MDS And AML